The 2026 midterm elections could have significant implications for pharmacy policy, with issues including pharmacy benefit manager (PBM) reform, pharmacy reimbursement, 340B contract pharmacy restrictions, Medicare coverage for pharmacist-provided services, and emerging direct-to-employer drug purchasing models all potentially affected by the balance of power in Congress.
Speaking with Drug Topics, A.J. Barbarito explained that pharmacies should expect continued attention to drug pricing, PBM practices, and healthcare affordability regardless of which party controls Congress. While the parties may take different approaches, bipartisan priorities such as PBM transparency could continue to advance. He also noted that executive action and agency rulemaking will remain important forces shaping healthcare policy, adding another layer of uncertainty for pharmacies navigating an evolving regulatory environment.
“Pharmacists are at the center of several health policy debates heading into the 2026 midterms. Congress has already enacted federal reforms, and additional measures are moving forward.”
Senior Associate
